N/A N=40 Motivational Interviewing for Weight Loss
Childhood Obesity
Primary: Weight Efficacy Life-style Questionnaire — 120.70; 128.80; 139.88; 136.40 scores on a scale — p=0.24
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8,202 HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
HIV · AIDS
Primary: Incidence Rate of Malignancies — 0.30; 0.27; 0.02; 0.62 malignancies per 100 person-years
Phase 3 N=606 Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 — -0.001; 0.126; 0.147 Liters — p=<0.001
Phase 2 N=120 Traveler's Diarrhea (TD) Automated Process
Prevention of Travelers' Diarrhea
Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer
Phase 3 N=350 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Primary Autonomic Failure · Dopamine Beta Hydroxylase Deficiency · Non-Diabetic Neuropathy
Primary: Patients With Treatment-emergent Adverse Events — 263 participants
Phase 2 N=9 Botulin-A Toxin Instillations and Overactive Bladder
Overactive Bladder · Detrusor Instability · Detrusor Hyperreflexia
Primary: Median Number of Incontinent Episodes During 24 Hours — 4; 2; 4 number of incontinent episodes — p=0.004
Phase 4 N=74 Tenaculum Pain Control Study
Cervical Pain · Pelvic Pain
Primary: Tenaculum Pain — 12.3; 36.6 mm
Phase 3 N=158 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
Pneumococcal Conjugate Vaccine
Primary: Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2 — 0.75; 0.89…
Phase 4 N=56 A Comparison of Three Different Formulations of Prednisolone Acetate 1%
Glaucoma · Cataract
Primary: Percent Change in Flare at Resolution — 64.8; 68.3; 65.7 Percent change in flare
Phase 3 N=510 Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
Back Pain Lower Back Chronic
Primary: Mean Change in 24-hour Pain Intensity Ratings Scale (NRS). — 0.48; 0.96 units on a scale
Phase 1 N=13 Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine
Hypertension
Primary: Maximal Change From Baseline in Standing SBP — -7.42; -4.42 mmHg
N/A N=105 The Registry to Study Safety and Performance of the CORDIS Vascular Reconstruction Device and Delivery System
Intracranial Aneurysm
Primary: The Successful Intracranial VRD Placement With Satisfactory Coil Mass Position Without the Occurrence of Any Device and/or Procedure Related Serious Adverse Event (SAE)…
Phase 4 N=49 Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
Primary Total Hip and Knee Arthroplasty
Primary: Blood Loss — 6; 1 participants
N/A N=10,673 A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults
Hypopituitarism · Pituitary Insufficiency · Growth Hormone Deficiency, Adult
Primary: Clinically Significant Adverse Events — 2.58; 3.78; 4.0; 5.3 percentage of participants
Phase 1 N=30 Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers
Healthy Volunteers
Primary: Area Under the Plasma Concentration-time Curve (AUC) for Lisdexamfetamine Dimesylate — 27.0; 36.0; 38.3 ng*hr/ml